Cidara Therapeutics, Inc.
CDTX
Rank in Stocks
#3185
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Share Price
$221.38
Last synced: 2026-01-08
Market Cap
$5.61B
Change (1 day)
0.00%
Change (1 year)
118.07%
Country
US
Trade Cidara Therapeutics, Inc. (CDTX)
Category
Healthcare
Revenue for Cidara Therapeutics, Inc. (CDTX)
Revenue in Sep 2025 TTM: 0.00
According to Cidara Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0.00. In 2023 the company made a revenue of $23.28M a decrease compared to the revenue in the year 2022 that was $64.45M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cidara Therapeutics, Inc. from 2012 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | $1.28M | -94.52% |
| 2023 | $23.28M | -63.87% |
| 2022 | $64.45M | 30.01% |
| 2021 | $49.57M | 310.81% |
| 2020 | $12.07M | -42.30% |
| 2019 | $20.92M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
